Back to Report Store Home

Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth

  • Published: Nov-2015
  • Report Code: GBIHC373MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Prostate Cancer Therapeutics, Treatment, Stages I and II 18

Figure 2: Prostate Cancer Therapeutics, Treatment, Stage III 19

Figure 3: Prostate Cancer Therapeutics, Treatment, Stage IV 27

Figure 4: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed Products, Hormone Sensitive Disease 28

Figure 5: Prostate Cancer Therapeutics, Safety Results for Key Parameters – Marketed Products, Hormone Sensitive Disease 29

Figure 6: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed Products, First-line Treatment mCRPC 30

Figure 7: Prostate Cancer Therapeutics, Safety Results for Key Parameters – Marketed Products, First-line Treatment mCRPC 31

Figure 8: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed Products, Second-line Treatment mCRPC 32

Figure 9: Prostate Cancer Therapeutics, Safety Results for Key Parameters – Marketed Products, Second-line Treatment mCRPC 33

Figure 10: Prostate Cancer Therapeutics, Global, Overview of Pipeline Products 46

Figure 11: Prostate Cancer Therapeutics, Global, Mechanisms of Action 49

Figure 12: Prostate Cancer Therapeutics, Global, Mechanisms of Action 50

Figure 13: Prostate Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2006–2015 51

Figure 14: Market Prostate Cancer Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006–2015 52

Figure 15: Prostate Cancer Therapeutics, Global, Clinical Trial Failure Rate by Mechanism of Action (%), 2006–2015 53

Figure 16: Prostate Cancer Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006–2015 54

Figure 17: Prostate Cancer Therapeutics, Global, Clinical Trial Duration by Mechanism of Action (months), 2006–2015 56

Figure 18: Prostate Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006–2015 58

Figure 19: Prostate Cancer Therapeutics, Global, Clinical Trial Size per Product by Mechanism of Action (participants), 2006–2015 59

Figure 20: Prostate Cancer Therapeutics, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006–2015 60

Figure 21: Prostate Cancer Therapeutics, Global, Clinical Trial Size of Products by Mechanism of Action (participants), 2006–2015 61

Figure 22: Prostate Cancer Therapeutics, Global, Tookad Revenue Forecast ($m), 2018–2021 64

Figure 23: Prostate Cancer Therapeutics, Global, ProstAtak Revenue Forecast ($m), 2019–2021 66

Figure 24: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters – Pipeline Products, Localized Disease 67

Figure 25: Prostate Cancer Therapeutics, Safety Results for Key Parameters – Pipeline Products, Localized Disease 68

Figure 26: Prostate Cancer Therapeutics, Global, ODM-201 Forecast Revenue ($m), 2018–2021 70

Figure 27: Prostate Cancer Therapeutics, Global, Prostvac Revenue Forecast ($m), 2017–2021 72

Figure 28: Prostate Cancer Therapeutics, Global, ARN-509 Revenue Forecast ($m), 2020–2021 74

Figure 29: Prostate Cancer Therapeutics, Global, Custirsen Sodium Revenue Forecast ($m), 2017–2021 77

Figure 30: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed (Highlighted in Blue) and Pipeline Products, mCRPC – First Line 78

Figure 31: Prostate Cancer Therapeutics, Safety Results for Key Parameters – Marketed (Highlighted in Blue) and Pipeline Products, mCRPC – First Line 79

Figure 32: Prostate Cancer Therapeutics, Global, DCVAC Revenue Forecast ($m), 2019–2021 81

Figure 33: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed (Highlighted in Blue) and Pipeline Products, mCRPC – Second Line 83

Figure 34: Prostate Cancer Therapeutics, Global, Treatment Usage Patterns (‘000), 2014–2021 85

Figure 35: Prostate Cancer Therapeutics, Global, Market Size ($bn), 2014–2021 86

Figure 36: Prostate Cancer Therapeutics, US, Treatment Usage Patterns (‘000) and Annual Cost of Therapy ($), 2014–2021 87

Figure 37: Prostate Cancer Therapeutics, US, Market Revenue ($m), 2014–2021 88

Figure 38: Prostate Cancer Therapeutics, Canada, Treatment Usage Patterns and ACoT (‘000; $), 2014–2021 90

Figure 39: Prostate Cancer Therapeutics, Canada, Market Revenue ($m), 2014–2021 91

Figure 40: Prostate Cancer Therapeutics, Top Five European Markets, Treatment Usage Patterns (‘000), 2014–2021 92

Figure 41: Prostate Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2014–2021 94

Figure 42: Prostate Cancer Therapeutics, Top Five European Markets, Market Revenue ($m), 2014–2021 95

Figure 43: Prostate Cancer Therapeutics, Japan, Treatment Usage Patterns and Annual Cost of Therapy (‘000; $), 2014–2021 97

Figure 44: Prostate Cancer Therapeutics, Japan, Market Revenue ($m), 2014–2021 98

Figure 45: Prostate Cancer Therapeutics, Global, Co-Development Deals by Region, Value and Year, 2006–2014 103

Figure 46: Prostate Cancer Therapeutics, Global, Co-Development Deals by Molecule Type, 2006–2014 104

Figure 47: Prostate Cancer Therapeutics, Global, Co-Development Deals by Molecule Type, 2006–2014 105

Figure 48: Prostate Cancer Therapeutics, Global, Licensing Deals by Value and Year, 2006–2014 108

Figure 49: Prostate Cancer Therapeutics, Global, Licensing Deals by Phase and Molecule Type, 2006–2014 109

Figure 50: Prostate Cancer Therapeutics, Global, Licensing Deals by Mechanism of Action, 2006–2014 110

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards